3 Branded Generics Maker, Data Analytics Services Company and Light Commercial Vehicles Maker Stocks With a Strong Future Roadmap: Glenmark Pharmaceuticals, Latent View Analytics and Force Motors
- November 19, 2026
- Posted by: Ankit Jaiswal
- Category: Best Stocks
Glenmark Pharmaceuticals, Latent View Analytics and Force Motors: ROE of 11.3% to 28.1% and FY22 to FY26 revenue CAGR of 8.7% to 29.2%. Prices as of 18 Nov 2026.
Quick Answer
The three migraine drug, analytics and trucks stocks to watch are Glenmark Pharmaceuticals, Latent View Analytics and Force Motors. Their return on equity ranges from 11.3% to 28.1%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.7% to 29.2%. Glenmark Pharmaceuticals has the highest return on equity at 28.1%, while Force Motors has the fastest revenue growth at 29.2% a year. Prices are based on the 18 November 2026 close, and this article is educational, not investment advice.
Migraine drug, analytics and trucks stocks offer a focused view of a sector where demand keeps widening. Glenmark Pharmaceuticals, Latent View Analytics and Force Motors cover a branded generics maker, a data analytics services company and a light commercial vehicles maker.
This list covers three migraine drug, analytics and trucks stocks with complete current figures: Glenmark Pharmaceuticals, Latent View Analytics and Force Motors. Every figure comes from the latest reported financials and the 18 November 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Migraine Drug, Analytics and Trucks Stocks?
Migraine drug, analytics and trucks stocks are listed companies that make branded and generic medicines for skin, respiratory and other conditions, provide data and analytics services to global brands, and make vans, light trucks and utility vehicles. Their earnings depend on medicine demand, client data budgets and vehicle sales.
Migraine Drug, Analytics and Trucks Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Glenmark Pharmaceuticals | 2,646.1 | 60,103 | 33.4 | 35.7 | 28.1 | 0.06 |
| Latent View Analytics | 190.17 | 4,968 | 25.0 | 17.5 | 11.3 | 0.02 |
| Force Motors | 20,088 | 23,296 | 18.6 | 24.1 | 25.2 | 0.00 |
On valuation, Glenmark Pharmaceuticals and Force Motors trade at a P/E below the industry P/E, while Latent View Analytics trades above it, which reflects the growth the market already expects. Readers comparing migraine drug, analytics and trucks stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.
Why Do Migraine Drug, Analytics and Trucks Stocks Have a Strong Roadmap in India?
Migraine drug, analytics and trucks stocks have a strong roadmap in India because steady demand for medicines, rising client spending on data and analytics and rising demand for utility vehicles keep widening the market for these companies.
- Branded generics. Patients need affordable medicines.
- Data analytics. Brands use data to plan sales.
- Light trucks. Small businesses need delivery vehicles.
Why Glenmark Pharmaceuticals Features Among These Migraine Drug, Analytics and Trucks Stocks
Among the migraine drug, analytics and trucks stocks on this list, Glenmark Pharmaceuticals is a research-driven pharma company with branded generics in India and other emerging markets, generics in the United States and Europe, and an innovation arm focused on new drugs.
Revenue rose from Rs 12,472 crore in FY22 to Rs 17,443 crore in FY26, a compound annual growth rate of 8.7%. Net profit grew from Rs 994 crore in FY22 to Rs 1,362 crore in FY26, which works out to a compound annual growth rate of 8.2%.
In the June 2026 quarter, revenue grew 24.1% year on year to Rs 4,084 crore. The company has a return on equity of 28.1%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 60,103 crore. The stock trades at a P/E of 33.4, below the industry P/E of 35.7.
Roadmap: The company is strengthening its dermatology and respiratory franchises and advancing its innovation pipeline, which could add higher-value income. Growth in India and emerging markets supports steady sales.
What to watch: Track new product launches, progress in the innovation pipeline and balance sheet strength.
Why Latent View Analytics Features Among These Migraine Drug, Analytics and Trucks Stocks
Among the pharma innovator, data science and commercial vehicle shares on this list, Latent View Analytics, headquartered in Chennai, provides data analytics, engineering and artificial intelligence services to technology, consumer and financial clients worldwide.
In the June 2026 quarter, revenue grew 18.8% year on year to Rs 308 crore. Revenue rose from Rs 429 crore in FY22 to Rs 1,136 crore in FY26, a compound annual growth rate of 27.6%.
Net profit grew from Rs 130 crore in FY22 to Rs 202 crore in FY26, which works out to a compound annual growth rate of 11.8%. The company has a return on equity of 11.3%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 4,968 crore. The stock trades at a P/E of 25.0, above the industry P/E of 17.5.
Roadmap: Enterprises are investing in analytics and artificial intelligence, which feeds demand for data services. The company is widening its client list and scaling large accounts with a consulting and engineering model.
What to watch: Follow client additions and the growth of large accounts.
Why Force Motors Features Among These Migraine Drug, Analytics and Trucks Stocks
Among the three companies on this list, Force Motors, based in Pune, makes light commercial vehicles such as the Traveller and Gurkha, and supplies engines and axles to global carmakers.
The company has a return on equity of 25.2%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 23,296 crore. The stock trades at a P/E of 18.6, below the industry P/E of 24.1.
Revenue rose from Rs 3,292 crore in FY22 to Rs 9,168 crore in FY26, a compound annual growth rate of 29.2%. Net profit grew from Rs 801 crore in FY25 to Rs 1,212 crore in FY26, a rise of 51.3%. In the June 2026 quarter, revenue grew 6.7% year on year to Rs 2,478 crore, while net profit rose 22.8% to Rs 217 crore.
Roadmap: Its traveller and ambulance range, defence vehicle supply and contract manufacturing for international partners give it several growth routes. It has no debt on its books, which leaves room for investment in new models.
What to watch: Track order flow from state transport and defence customers.
Glenmark Pharmaceuticals vs Latent View Analytics vs Force Motors on Key Financials
The table below sets the three migraine drug, analytics and trucks stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Glenmark Pharmaceuticals | 12,472 | 17,443 | 8.7% | 1,362 | 7.8% |
| Latent View Analytics | 429 | 1,136 | 27.6% | 202 | 17.8% |
| Force Motors | 3,292 | 9,168 | 29.2% | 1,212 | 13.2% |
Glenmark Pharmaceuticals posts the highest return on equity in this group at 28.1%. Glenmark Pharmaceuticals has the largest FY26 revenue at Rs 17,443 crore, and Force Motors shows the fastest revenue growth with a 29.2% compound annual rate. A useful habit with migraine drug, analytics and trucks stocks is to check each new quarterly result against the capacity plans the company described earlier.
The June 2026 quarter, the latest reported, gives a fresh read on momentum:
| Company | Q1 FY26 Revenue (Rs Cr) | Q1 FY27 Revenue (Rs Cr) | Year-on-Year Growth |
|---|---|---|---|
| Glenmark Pharmaceuticals | 3,291 | 4,084 | 24.1% |
| Latent View Analytics | 259 | 308 | 18.8% |
| Force Motors | 2,322 | 2,478 | 6.7% |
Key Risks to Check Before Investing in Migraine Drug, Analytics and Trucks Stocks
Every theme carries risks that deserve a check before any decision. For these migraine drug, analytics and trucks stocks, the main points are: Long-term pharma innovator, data science and commercial vehicle shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Regulatory approvals. Plant inspections and approvals can affect supplies.
- Client spending. Technology budgets can vary with global conditions.
- Demand cycles. Sales can vary with seasons and rates.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter migraine drug, analytics and trucks stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Migraine Drug, Analytics and Trucks Stocks
Migraine drug, analytics and trucks stocks reward patient research into demand, execution and financial strength. Glenmark Pharmaceuticals, Latent View Analytics and Force Motors each have a clear plan to grow. Based on the 18 November 2026 close, Glenmark Pharmaceuticals trades at Rs 2,646.1, Latent View Analytics at Rs 190.17 and Force Motors at Rs 20,088. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these migraine drug, analytics and trucks stocks to a watchlist.
Download the Univest iOS App or Univest Android App to track migraine drug, analytics and trucks stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are migraine drug, analytics and trucks stocks?
Ans. Migraine drug, analytics and trucks stocks are listed companies that make branded and generic medicines for skin, respiratory and other conditions, provide data and analytics services to global brands, and make vans, light trucks and utility vehicles. Their earnings depend on medicine demand, client data budgets and vehicle sales. This list looks at three of them, Glenmark Pharmaceuticals, Latent View Analytics and Force Motors, using reported FY22 to FY26 financials and the 18 November 2026 closing prices.
Which migraine drug, analytics and trucks stocks are covered in this list?
Ans. This list covers Glenmark Pharmaceuticals, Latent View Analytics and Force Motors. Based on the 18 November 2026 close, Glenmark Pharmaceuticals traded at Rs 2,646.1, Latent View Analytics at Rs 190.17 and Force Motors at Rs 20,088. Their return on equity ranges from 11.3% to 28.1%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.7% to 29.2%.
Why do migraine drug, analytics and trucks stocks have a strong future roadmap in India?
Ans. Migraine drug, analytics and trucks stocks have a strong roadmap in India because steady demand for medicines, rising client spending on data and analytics and rising demand for utility vehicles keep widening the market for these companies. The main drivers are as follows. Branded generics. Patients need affordable medicines. Data analytics. Brands use data to plan sales. Light trucks. Small businesses need delivery vehicles. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Glenmark Pharmaceuticals performed financially?
Ans. Revenue rose from Rs 12,472 crore in FY22 to Rs 17,443 crore in FY26, a compound annual growth rate of 8.7%. Net profit grew from Rs 994 crore in FY22 to Rs 1,362 crore in FY26, which works out to a compound annual growth rate of 8.2%. In the June 2026 quarter, revenue grew 24.1% year on year to Rs 4,084 crore. The company has a return on equity of 28.1%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 60,103 crore. The stock trades at a P/E of 33.4, below the industry P/E of 35.7. Looking ahead, the company is strengthening its dermatology and respiratory franchises and advancing its innovation pipeline, which could add higher-value income. Growth in India and emerging markets supports steady sales.
How has Latent View Analytics performed financially?
Ans. Revenue rose from Rs 429 crore in FY22 to Rs 1,136 crore in FY26, a compound annual growth rate of 27.6%. Net profit grew from Rs 130 crore in FY22 to Rs 202 crore in FY26, which works out to a compound annual growth rate of 11.8%. In the June 2026 quarter, revenue grew 18.8% year on year to Rs 308 crore. The company has a return on equity of 11.3%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 4,968 crore. The stock trades at a P/E of 25.0, above the industry P/E of 17.5. Looking ahead, enterprises are investing in analytics and artificial intelligence, which feeds demand for data services. The company is widening its client list and scaling large accounts with a consulting and engineering model.
How has Force Motors performed financially?
Ans. Revenue rose from Rs 3,292 crore in FY22 to Rs 9,168 crore in FY26, a compound annual growth rate of 29.2%. Net profit grew from Rs 801 crore in FY25 to Rs 1,212 crore in FY26, a rise of 51.3%. In the June 2026 quarter, revenue grew 6.7% year on year to Rs 2,478 crore, while net profit rose 22.8% to Rs 217 crore. The company has a return on equity of 25.2%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 23,296 crore. The stock trades at a P/E of 18.6, below the industry P/E of 24.1. Looking ahead, its traveller and ambulance range, defence vehicle supply and contract manufacturing for international partners give it several growth routes. It has no debt on its books, which leaves room for investment in new models.
What risks should investors check before buying migraine drug, analytics and trucks stocks?
Ans. Investors should check a few risks before buying migraine drug, analytics and trucks stocks. Regulatory approvals. Plant inspections and approvals can affect supplies. Client spending. Technology budgets can vary with global conditions. Demand cycles. Sales can vary with seasons and rates. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of migraine drug, analytics and trucks stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 18 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.